Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cabazitaxel in platinum refractory ovarian cancer. A phase II trial

Trial Profile

Cabazitaxel in platinum refractory ovarian cancer. A phase II trial

Phase of Trial: Phase II

Latest Information Update: 09 Dec 2014

At a glance

  • Drugs Cabazitaxel (Primary)
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Acronyms TaxOvar
  • Most Recent Events

    • 03 Dec 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 11 Dec 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT01747239).
    • 11 Dec 2012 Planned End Date changed from 13 Feb 2015 to 1 Oct 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top